METHOD FOR PREDICTION OF INTERFERON SENSITIVITY IN PATIENTS SUFFERING RENAL CELL CARCINOMA Russian patent published in 2011 - IPC G01N33/573 G01N33/49 

FIELD: medicine.

SUBSTANCE: prior to the initiation of bioluminescent IF therapy, enzymatic activity in patient's peripheral blood lymphocytes is evaluated: including glucose-6-phosphate dehydrogenase (G6PDG), malate dehydrogenase (MDG), NADP-dependent glutamate dehydrogenase (NADPGDG) and NAD-dependent glutamate dehydrogenase (NADGDG). A relation coefficient of a plastic and energy metabolism (RPEM) representing the relation of a product of G6PDG and NADPGDG activities to a product of MDG and NADGDG activities. If the RPEM value is equal to or more than 0.12, interferon sensitivity is predicted, while the RPEM value less than 0.12 enables to predict interferon resistance.

EFFECT: use of the method allows predicting adequately cell interferon sensitivity of the patients with renal cell carcinoma prior to the initiation of the IF therapy and can be recommended for application in clinical practice.

2 tbl